Balance Sheet
AssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Other Accumulated Expenses (2019 - 2025)

Benitec Biopharma's Other Accumulated Expenses history spans 7 years, with the latest figure at $157000.0 for Q1 2025.

  • For Q1 2025, Other Accumulated Expenses changed N/A year-over-year to $157000.0; the TTM value through Mar 2025 reached $157000.0, changed N/A, while the annual FY2024 figure was $138000.0, 100.0% up from the prior year.
  • Other Accumulated Expenses for Q1 2025 was $157000.0 at Benitec Biopharma, up from $92000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $223000.0 in Q4 2021 and bottomed at $36000.0 in Q1 2023.
  • The 5-year median for Other Accumulated Expenses is $80000.0 (2021), against an average of $97875.0.
  • The largest annual shift saw Other Accumulated Expenses skyrocketed 145.05% in 2021 before it tumbled 81.61% in 2022.
  • A 5-year view of Other Accumulated Expenses shows it stood at $223000.0 in 2021, then plummeted by 81.61% to $41000.0 in 2022, then soared by 80.49% to $74000.0 in 2023, then grew by 24.32% to $92000.0 in 2024, then surged by 70.65% to $157000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Other Accumulated Expenses are $157000.0 (Q1 2025), $92000.0 (Q4 2024), and $59000.0 (Q3 2024).